Comparing NewLink Genetics (NLNK) & OpGen (OPGN)

NewLink Genetics (NASDAQ: NLNK) and OpGen (NASDAQ:OPGN) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations.

Insider and Institutional Ownership

52.6% of NewLink Genetics shares are held by institutional investors. Comparatively, 11.8% of OpGen shares are held by institutional investors. 13.7% of NewLink Genetics shares are held by company insiders. Comparatively, 17.4% of OpGen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and target prices for NewLink Genetics and OpGen, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NewLink Genetics 0 0 6 0 3.00
OpGen 0 0 2 0 3.00

NewLink Genetics currently has a consensus price target of $25.67, suggesting a potential upside of 199.15%. OpGen has a consensus price target of $1.00, suggesting a potential upside of 488.24%. Given OpGen’s higher possible upside, analysts plainly believe OpGen is more favorable than NewLink Genetics.

Profitability

This table compares NewLink Genetics and OpGen’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
NewLink Genetics -229.19% -63.39% -47.83%
OpGen -533.47% -1,289.51% -234.78%

Risk and Volatility

NewLink Genetics has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Comparatively, OpGen has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500.

Earnings and Valuation

This table compares NewLink Genetics and OpGen’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
NewLink Genetics $35.77 million 8.89 -$85.15 million ($2.44) -3.52
OpGen $4.03 million 2.38 -$19.16 million ($0.62) -0.27

OpGen has lower revenue, but higher earnings than NewLink Genetics. NewLink Genetics is trading at a lower price-to-earnings ratio than OpGen, indicating that it is currently the more affordable of the two stocks.

Summary

NewLink Genetics beats OpGen on 8 of the 13 factors compared between the two stocks.

About NewLink Genetics

NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

About OpGen

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.

Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply